Skip to main content

Cytokinetics Value Stock - Dividend - Research Selection

Cytokinetics

ISIN: US23282W6057 , WKN: A1W1KK

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company\'s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Cytokinetics (CYTK) Investor Presentation - Slideshow

2023-03-17
The following slide deck was published by Cytokinetics, Incorporated in conjunction with this event.

Mizuho Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)

2023-03-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Aldeyra Therapeutics (ALDX)

2023-03-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cantor Fitzgerald Sticks to Their Buy Rating for Cytokinetics (CYTK)

2023-03-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cytokinetics to Participate in Upcoming Investor Conferences

2023-03-06
SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Oppenheimer 33rd Annual Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will present virtually on Monday, March 13, 2023 at 10:00 AM Eastern Time.Barclays Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will participate in a Fi

Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle

2023-03-06
Cytokinetics Incorporated (NASDAQ: CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At ten weeks, patients in Cohort 4 experienced significant improvements in NT-proBNP, with an average decrease of 66%. High-sensitivity troponin I level also improved significantly proportional to baseline at each study visit. Related: FDA Rejects Cytokinetics' Heart Failure Treatment Candidate. An improvement of ≥

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Seagen (SGEN) and BioVie (BIVI)

2023-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Qiagen (QGEN) and Dice Therapeutics (DICE)

2023-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Puma Biotechnology (PBYI) and Praxis Precision Medicines (PRAX)

2023-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts` Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK), Incyte (INCY) and Seer (SEER)

2023-03-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.